Compare LGIH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | SANA |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2013 | 2021 |
| Metric | LGIH | SANA |
|---|---|---|
| Price | $47.83 | $5.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $71.13 | $7.83 |
| AVG Volume (30 Days) | 330.9K | ★ 5.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $1,788,933,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.70 | $1.26 |
| 52 Week High | $104.31 | $7.30 |
| Indicator | LGIH | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 61.91 |
| Support Level | $46.73 | $4.25 |
| Resistance Level | $50.54 | $5.43 |
| Average True Range (ATR) | 2.17 | 0.50 |
| MACD | -0.36 | 0.13 |
| Stochastic Oscillator | 10.77 | 87.35 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.